AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers

by Barry101 | Dec 24, 2020 | Press Release, Uncategorized

AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers’ Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects OCALA, FL / December 24, 2020 /...

AIM ImmunoTech Inc.’s Drug Ampligen Awarded FDA’s Orphan Drug Designation Status for the Treatment of Pancreatic Cancer

by Barry101 | Dec 21, 2020 | Press Release, Uncategorized

OCALA, Fla., Dec. 21, 2020 — AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that the U.S. Food...

AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19

by Barry101 | Nov 25, 2020 | Press Release, Uncategorized

OCALA, Fla., Nov. 25, 2020 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced developments in its work to develop new treatments or preventive strategies for COVID-19, the disease caused by SARS-CoV-2.First, AIM reports that Roswell Park Comprehensive...

AIM ImmunoTech Provides Third Quarter 2020 Business Update

by Barry101 | Nov 13, 2020 | Press Release, Uncategorized

OCALA, Fla., Nov. 13, 2020 — AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today provided a business update for...

AIM ImmunoTech Announces PLOS ONE’s Publication of New Data Analyses Showing Importance of Disease Duration on Ampligen’s Positive Role in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

by Barry101 | Nov 2, 2020 | Press Release, Uncategorized

Early Onset Therapy May Be Key to COVID Long Hauler SyndromeOCALA, Fla., Nov. 02, 2020 — AIM ImmunoTech Inc. (NYSE American: AIM) announced today the publication of statistically significant data detailing how its drug Ampligen could have a considerable positive...

BioFlorida Names AIM ImmunoTech CEO Thomas K. Equels as Entrepreneur of the Year

by Barry101 | Oct 30, 2020 | Press Release, Uncategorized

TAMPA, Fla. and OCALA, Fla., Oct. 30, 2020 — BioFlorida has announced Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech Inc. (NYSE American: AIM), as its Weaver H. Gaines Entrepreneur of the Year. The Entrepreneur of the Year Award recognizes an...